Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCapecitabine
Dr. Neelima Denduluri, MD
NPI1861698946
- Medicare services, 2021
- 696
- Part D claims, 2021
- 192
- Publications
- 43
- Clinical trials
- 9
- Industry payments
- $10,514
- Practice address
- 1635 N George Mason Dr, Arlington, VA 22205-3633
- Practice phone
- Call (703) 528-7303
- Professional email
- Get professional email
- Personal email
- Get personal email
- Mobile number
- Get mobile number
Find Dr. Denduluri's professional email, personal email and mobile number
Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.
Dr. Neelima Denduluri is a hematologist and oncologist in Arlington, Virginia
Dr. Denduluri practices in Arlington, Virginia.
Dr. Denduluri's NPI, 1861698946, was assigned on June 25, 2007. Dr. Denduluri holds Virginia license 0101231329.
NPI and contact details
- NPI
- 1861698946NPI Registry (opens in a new tab)
- NPI enumeration date
- June 25, 2007
- NPI status
- Active
- Practice phone
- (703) 528-7303
- Professional email
- Get email
- Personal email
- Get email
- Mobile number
- Get number
- Sex
- Female
Sources: NPPES NPI Registry (CMS); and Dmand AI Professional Profile Data
Dr. Neelima Denduluri's practice address is in Arlington, Virginia
Dr. Denduluri's practice address in the NPI Registry is 1635 N George Mason Dr, Arlington, VA 22205-3633. The practice phone is (703) 528-7303.
- NPI Registry address1635 N George Mason Dr, Arlington, VA 22205-3633Phone(703) 528-7303
Sources: NPPES NPI Registry (CMS); and Dmand AI Practice Data
Dmand AI tracks the EHR system at Dr. Neelima Denduluri's practice
Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denduluri practices. Vendor and product names are available with a free account.
| Site | EHR vendor and product |
|---|---|
| Dr. Denduluri's practice | Available with a free account |
Source: Dmand AI Technology Install Data
For health IT teams
See the EHR and IT leaders at every site where Dr. Denduluri practices
Dmand AI maps EHR vendors, IT decision makers and buying committees across each health system and 6.2K+ hospitals, with verified contacts in the same login.
Dr. Neelima Denduluri is one of 297 hematologists and oncologists in Virginia
Hematology and oncology is Dr. Denduluri's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Denduluri's licenses on file in 2 states: Virginia and District of Columbia.
Specialties and state licenses
- Hematology and oncology, VirginiaPrimary
- District of Columbia license
Hematologists and oncologists near Dr. Denduluri
Counts of hematologists and oncologists with a Dmand AI profile, by place and practice. Each opens the list.
297hematologists and oncologists in Virginia
8hematologists and oncologists in Arlington
Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks
Dr. Neelima Denduluri billed Medicare for 696 services in 2021
CMS data shows 696 Medicare services from Dr. Denduluri across 9 procedure codes in 2021. Medicare paid $15,834 for them. Every service was in an office.
Medicare services, 2021696
Paid by Medicare$15,834
Procedure codes9
Dr. Denduluri's Medicare services by type, 2020 to 2021
- 2020
- 2021
- Drugs given in the office
- 2020: 49,7582021: 39099%
- Office and hospital visits
- 2020: 6912021: 9486%
- Tests and treatments
- 2020: 1,1812021: 8393%
- Lab and pathology
- 2020: 4682021: 5588%
- Surgery
- 2020: 3642021: 4089%
- Other services
- 2020: 4832021: 3493%
Dr. Denduluri compared with the Virginia median for hematologists and oncologists, 2021
- Dr. Denduluri
- Virginia median
- Medicare services
- 696vs 3,51480% below
- Part D claims
- 192vs 45258% below
Medians across 275 hematologists and oncologists in Virginia with Dmand AI profiles that report each measure.
Dr. Denduluri's most billed Medicare procedure codes, 2021
CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.
Need commercial claims for Dr. Denduluri?
Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Denduluri and other hematologists and oncologists in Virginia.
Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks
Dr. Neelima Denduluri's patients have a median age of 56
Across all payers, Dmand AI patient panel data puts Dr. Denduluri's median patient age at 56, with 100% women.
Dr. Denduluri's patients across all payers
Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.
Patient panel by age, all payers
Median age 56
Patient panel by sex, all payers
- Women100%
- Men0%
Source: Dmand AI Patient Panel Data
Dr. Neelima Denduluri wrote 192 Medicare Part D claims in 2021
In 2021, Dr. Denduluri wrote 192 Medicare Part D claims. Every claim was for a generic drug. They cover 4 drugs, with $8,136 in total drug cost. In 2020, CMS named 400 claims across 8 drugs.
Part D claims, 2021192
Drugs named by CMS4
Total drug cost$8,136
Dr. Denduluri's most prescribed drugs by claims, 2021
CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.
Part D claims for drugs CMS names, 2020 to 2021
- 2020
- 2021
- Claims for drugs CMS names
- 2020: 4002021: 19252%
Drugs named by CMS: 4 in 2021, 8 in 2020.
Source: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026
For MedTech and pharma teams
Find hematologists and oncologists like Dr. Denduluri by procedure volume and prescribing
Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.
Dr. Neelima Denduluri has 43 publications on record
Dmand AI links 43 papers to Dr. Denduluri, published from 2011 to 2024. 2019 was the busiest year, with 8. The most frequent topics are Breast Neoplasms, Receptor, ErbB-2 and Antineoplastic Combined Chemotherapy Protocols. Dr. Denduluri has published most often in J Clin Oncol. Dr. Denduluri's most frequent co-authors are Jeanne Mandelblatt, MD, Asma Ali Dilawari, MD and Martine Extermann, MD.
Papers43
Years published2011 to 2024
Dr. Denduluri's papers by year, 2015 to 2024
Topics Dr. Denduluri writes about most
- Breast Neoplasms
- Receptor, ErbB-2
- Antineoplastic Combined Chemotherapy Protocols
- Chemotherapy, Adjuvant
- Medical Oncology
- Antineoplastic Agents
- Double-Blind Method
- Breast
Dr. Denduluri's most frequent co-authors
- Jeanne Mandelblatt, MD6 shared papers
- Asma Ali Dilawari, MD4 shared papers
- Martine Extermann, MD4 shared papers
Recent publications by Dr. Denduluri
Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDouble-Blind Method
See who Dr. Denduluri researches with
Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Denduluri works with, so you can find a warm path to the right hematologists and oncologists.
Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage
Dr. Neelima Denduluri has worked on 9 clinical trials
Dmand AI links Dr. Denduluri to 9 clinical trials, 3 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Triple Negative Breast Neoplasms. Novartis Pharmaceuticals sponsors the most, 3. Open Payments lists research payments to Dr. Denduluri that name 1 trial.
Clinical trials with Dr. Denduluri by phase
- 1Phase 1: 1 trial
- 3Phase 2: 3 trials
- 2Phase 3: 2 trials
- NonePhase 4: no trials
Trials with no phase (devices, behavioral studies) are left out.
Conditions in Dr. Denduluri's trials
- Breast Neoplasms
- Breast Diseases
- Triple Negative Breast Neoplasms
- Multiple Endocrine Neoplasia Type 1
- Multiple Endocrine Neoplasia
Investigators on the most trials with Dr. Denduluri
- Gail Lynn Wright, MD5 shared trials
- Paul D. Richards, MD4 shared trials
- Rachel Elizabeth Swart, MD, PhD4 shared trials
Recent clinical trials with Dr. Denduluri
Triple Negative Breast NeoplasmsBreast NeoplasmsBintrafusp alfa
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (opens in a new tab)
Active, not recruitingPhase 2
Breast NeoplasmsBreast DiseasesTrastuzumab deruxtecanTucatinib
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (opens in a new tab)
Active, not recruitingPhase 3
Breast NeoplasmsBreast DiseasesRibociclib
Triple Negative Breast NeoplasmsOvarian NeoplasmsEtrumadenantIPI-549nanoparticle albumin-bound paclitaxel (NP)
Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)
Dr. Neelima Denduluri received $10,514 in industry payments from 2016 to 2022
CMS Open Payments shows 55 general payments to Dr. Denduluri from 13 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 58% of the total. Daiichi Sankyo Inc. paid the most, $7,035. It also lists 5 research payments totaling $86,272 from 2016 to 2019, naming 1 clinical trial.
General payments to Dr. Denduluri by program year, 2016 to 2022
General payments to Dr. Denduluri by kind, 2016 to 2022
$10.5Kin total
- Consulting fees$6,06358%
- Food and beverage$1,54315%
- Travel and lodging$1,54015%
- Speaker and faculty fees$1,27012%
- Education$981%
Companies that paid Dr. Denduluri the most, 2016 to 2022
Share is of all general payments to this clinician.
Source: Open Payments (CMS), 2025 data, released July 7, 2026
Sources for Dr. Neelima Denduluri's profile data
| Data on this page | Source |
|---|---|
| NPI, name, sex, specialty and licenses | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data |
| Practice locations and phone | NPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Practice Data |
| Medicare services and procedure codes | Medicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab) |
| State medians for the same specialty | Dmand AI Peer Benchmarks |
| Medicare patients and the all-payer patient panel | Dmand AI Patient Panel Data |
| Part D prescribing | Medicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab) |
| Publications, topics and co-authors | PubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage |
| Clinical trials and co-investigators | Dmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab) |
| Industry payments | Open Payments (CMS) (opens in a new tab) |
| EHR at each practice site | Dmand AI Technology Install Data |
| Similar physicians | Dmand AI Affiliation Data |
Data last refreshed October 2026Report an inaccuracyRemove my information
FAQ
Frequently asked questions about Dr. Neelima Denduluri
Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.
What is Dr. Neelima Denduluri's NPI number?
Dr. Neelima Denduluri's NPI number is 1861698946. It was assigned on June 25, 2007, and it is active in the NPI Registry.
What kind of doctor is Dr. Neelima Denduluri?
Dr. Neelima Denduluri is a hematologist and oncologist in Arlington, Virginia. The primary specialty in the NPI Registry is Hematology & Oncology Physician (taxonomy code 207RH0003X).
Where does Dr. Neelima Denduluri practice?
Dr. Denduluri practices at 1635 N George Mason Dr, Arlington, VA 22205-3633.
What is Dr. Neelima Denduluri's office phone number?
The practice phone on file for Dr. Denduluri is (703) 528-7303.
What is Dr. Neelima Denduluri's medical license number?
Dr. Denduluri holds Virginia license 0101231329, one of the licenses on file in 2 states.
Which states has Dr. Neelima Denduluri been licensed in?
Dmand AI has state licenses on file for Dr. Denduluri in Virginia and District of Columbia.
Does Dr. Neelima Denduluri accept Medicare?
Yes. CMS data shows Dr. Denduluri billed Medicare for 696 services in 2021.
What services does Dr. Neelima Denduluri bill to Medicare?
In 2021, Dr. Denduluri's most billed Medicare services were injected or infused drug (J1100), office visit, established patient (99213) and lab and pathology test (85025).
What drugs does Dr. Neelima Denduluri prescribe most?
In 2021 Medicare Part D data, Dr. Denduluri's most prescribed drugs by claims were Letrozole, Anastrozole and Tamoxifen Citrate.
Has Dr. Neelima Denduluri received payments from drug or device companies?
CMS Open Payments shows $10,514 in general payments to Dr. Denduluri from 13 companies from 2016 to 2022. The largest total came from Daiichi Sankyo Inc.
Show 3 more questionsShow fewer questions
How long has Dr. Neelima Denduluri been practicing?
Dr. Denduluri's NPI was assigned in 2007.
Does Dr. Neelima Denduluri do research?
Dmand AI links 43 publications to Dr. Denduluri, published from 2011 to 2024. Dr. Denduluri has worked on 9 clinical trials.
Who does Dr. Neelima Denduluri publish with?
Dr. Denduluri's most frequent co-authors are Jeanne Mandelblatt, MD (6 shared papers), Asma Ali Dilawari, MD (4 shared papers) and Martine Extermann, MD (4 shared papers).
Selling to hematology and oncology practices?
See hematologists and oncologists in Virginia by site of care and group
Find the practices, groups and hospitals they work with, and the right people to contact at each.
- 30 days free
- Self-serve
- No credit card